SoulBio

Executive Summary

SoulBio is an Indian AI-driven bioinformatics company leveraging multi-omics data and deep learning to accelerate preclinical drug discovery. Founded in 2020 and based in Bengaluru, the company offers end-to-end platforms for target identification, biomarker discovery, drug repurposing, and patient stratification. By integrating diverse omics layers (genomics, proteomics, etc.) with proprietary AI models, SoulBio aims to reduce the time and cost of early-stage R&D for pharmaceutical partners. Despite being in the platform stage with a small team (10–50 employees) and no disclosed funding or valuation, the company operates in the high-growth oncology and immunology segments, where AI-powered discovery tools are increasingly sought after. Its focus on serving both biotech and large pharma, combined with India’s cost advantages, positions it as a potential disruptor in the preclinical informatics space. However, the lack of publicly announced customers, partnerships, or revenue traction limits visibility. SoulBio's success will depend on its ability to secure pilot projects, publish validation studies, and differentiate its platform from established competitors like Schrödinger and Recursion Pharmaceuticals. The company appears to be at an early commercialization stage, with moderate near-term risk.

Upcoming Catalysts (preview)

• Q4 2026First major pharma partnership or pilot program announcement30% success
• Q1 2027Series A funding round closure (targeting $5–10M)40% success
• Q3 2026Publication of validation study in peer-reviewed journal demonstrating platform's accuracy in target identification25% success